Jan. 21, 2025 — The NeurEYE research team, led by the University of Edinburgh, with Glasgow Caledonian University, has collected almost 1 million eye scans from opticians across Scotland, forming the world’s largest data set of its kind.

Jan. 10, 2025 – Bayer has announced positive topline results of the Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an investigational gadolinium-based contrast agent (GBCA) for use in magnetic resonance imaging (MRI).

All QUANTI studies investigated gadoquatrane at a gadolinium dose of 0.04 mmol Gd/kg body weight which represents a gadolinium dose reduction of 60 percent compared to the macrocyclic GBCAs dosed at 0.1 mmol Gd/kg body weight. Gadoquatrane successfully met the primary and main secondary endpoints of all QUANTI studies.

Jan. 10, 2024 —  ImagingU has announced the dates of its 2025 MRI Safety and MRSO Conferences.

ImagingU’s in-person weekend conferences are designed for current or aspiring MR Safety Officers, as well as other radiology professionals looking to increase their MRI safety knowledge or earn continuing education credits (CEUs).

The conferences will take place on:

Jan. 8, 2025 — ScreenPoint Medical has acquiredf Biomediq A/S, a research-based company focused on the research, development and implementation of quantitative imaging biomarkers. After a decade of close collaboration as separate entities on image based risk assessment, this deal is expected to bring breast cancer risk assessment capabilities to ScreenPoint's  Breast AI, Transpara.

Computed tomography (CT) has long been a cornerstone of modern imaging, providing detailed 3D insights into the human body and other materials. However, conventional CT requires hundreds of X-ray projections from multiple angles, exposing patients to significant radiation doses and relying on large, immobile systems.